The Non-Financial Ledger: What the Price Tag Never Covered

Think about the last time you trusted a product because the box told you to. You saw the words “no harsh ingredients” and “gynecologist tested” and you felt something — relief, maybe, or just the ordinary comfort of believing a company had done its job. You picked it up, put it in your cart, and moved on with your day. That is exactly what Kimberly-Clark was counting on.

For anyone who has used U by Kotex Click tampons over the past four years, here is what was happening inside their body while they went about their lives: lead was crossing the vaginal wall and entering the bloodstream. No liver to slow it down. No metabolic process to filter it out. Just direct absorption into systemic circulation — into the blood supply that feeds the pelvic organs, the kidneys, the brain.

Lead does not leave the body quickly. It accumulates. It settles into bone tissue. It disrupts neurological function. According to the complaint’s cited research, it can cause anemia, kidney damage, and seizures. In severe cases, coma and death. The World Health Organization has said, in language that does not hedge: there is no safe level of exposure.

The people using these tampons were not making an informed risk calculation. They were not told there was a risk. They were told the opposite. The box said “no harsh ingredients.” The box said “BPA free.” The box said “pesticide free.” Every single one of those marketing claims did one thing: it told you the company had thought carefully about what goes into this product and had made sure it was clean. It was a deliberate construction of trust.

Menstruating people use tampons during some of the most physically vulnerable and uncomfortable days of their month. They are already dealing with cramps, fatigue, and disrupted routines. The last thing they should have to do is investigate whether the product a billion-dollar corporation sold them as safe is quietly depositing a neurotoxin into their bloodstream up to six times a day.

Consider what the numbers actually mean in lived experience. The complaint states that most consumers use more than three tampons in a 24-hour period. The brand’s own website recommends changing every four to eight hours. That means six tampons per day is a realistic, normal usage pattern — and at six Super Plus tampons a day, a person is receiving 3.358 micrograms of lead directly into their blood. That is six times the legal limit California sets to protect reproductive health. A full menstrual cycle typically lasts three to seven days. The lead exposure stacks.

Lead is particularly dangerous, the complaint notes, for young people and women of childbearing age — precisely the demographic that is most likely to be using tampons. This is not a coincidence that cuts in Kimberly-Clark’s favor. It is a fact that makes their silence harder to defend.

Plaintiff Allison Barton bought these tampons at Target on March 17, 2023. She bought them again at Rite Aid in June 2024. She bought them because she had no reason not to. She read the label, saw the reassurances, and believed them. Kimberly-Clark was still selling the same product, with the same omission, when she made that second purchase — more than a year after the first.

The complaint makes clear that Kimberly-Clark knew or should have known the lead was there. They had a duty to test. They had a duty to disclose. They had a duty, under California law and under basic human decency, to put a warning on the box if they could not fix the problem. They did none of it. What they did instead was print more reassuring marketing language and keep moving product.

Legal Receipts: What the Complaint Actually Says

Every quote below comes directly from Case No. 3:24-cv-01337-GPC-KSC, filed in the United States District Court for the Southern District of California on July 30, 2024. Nothing has been paraphrased or invented.

“Defendant fails to disclose, and materially omits, that its U by KOTEX Click® compact tampons contain an unsafe amount of lead.”
— Complaint ¶1

• This is the foundational allegation. The complaint does not claim the lead is accidental or trace-level ambiguous. It calls it “unsafe” from the opening paragraph, anchoring the entire case in a clear factual claim backed by independent lab testing.
• The word “materially omits” is legally significant. A material omission under California consumer protection law is a fact that, if known, would have changed the consumer’s purchasing decision. The complaint argues lead absolutely meets that standard.

“There is no level of exposure to lead that is known to be without harmful effects.”
— World Health Organization, cited in Complaint ¶4

• This WHO statement is not a precautionary hedge. It is a scientific consensus position — no floor exists below which lead exposure is harmless. The complaint uses it to foreclose any defense that the amounts found were “too small to matter.”
• Combined with the fact that lead bypasses the liver entirely in vaginal use, this citation establishes that the route of exposure makes the risk worse, not better.

“Unlike food containing lead that is consumed orally, the Products do not metabolize, and the lead contained in the Products is not filtered by the liver. The lead contained in the Products can directly enter the bloodstream.”
— Complaint ¶¶7–8

• This is the critical pharmacological distinction the entire case rests on. Oral ingestion of a toxin gives the body one defensive system: first-pass metabolism through the liver. Vaginal insertion removes that defense entirely.
• The complaint cites peer-reviewed research on medication routes of administration and comparative vaginal/buccal permeability to support this claim. It is not a theoretical argument; it is established physiology.

“Based on independent laboratory testing and analysis, the Products contain .189 mcg of lead per gram of Product.”
— Complaint ¶33

• This figure is the quantitative spine of the lawsuit. By multiplying 0.189 mcg/gram by the known gram weights of each tampon size, the complaint produces precise daily exposure figures for Regular, Super, and Super Plus users at both three and six tampons per day.
• Every single resulting figure — all six calculations — exceeds California’s Proposition 65 MADL of 0.5 mcg/day for reproductive toxicity.

“The Product labels state, for example, that the Products contain ‘no harsh ingredients’; that they contain ‘elemental chlorine-free rayon’; and that they are ‘pesticide free’; ‘made without fragrance’; ‘gynecologist tested’; and ‘BPA free’.”
— Complaint ¶14

• The complaint frames each of these label claims as an active deception — not just a lie of omission, but a lie of commission. By highlighting specific safe ingredients and testing credentials, Kimberly-Clark created the impression that the product had been thoroughly screened for harm.
• The complaint notes these representations are voluntary. They are not required by any government or FDA regulation. Kimberly-Clark chose to put them on the box to drive sales, which makes their deceptive effect legally actionable.

“Defendant had an improper motive — to derive financial gain at the expense of accuracy or truthfulness — in its practices related to the labeling and advertising of the Products.”
— Complaint ¶124

• This is the complaint’s most direct statement of intent. The lawsuit alleges Kimberly-Clark was not merely negligent — the omission was driven by a financial motive. Disclosing lead would hurt sales, so they did not disclose it.
• This allegation supports the “unfair” prong of California’s Unfair Competition Law, which requires showing that the harm to consumers outweighs any legitimate business justification for the conduct.

“Defendant continues to sell the misbranded Products.”
— Complaint ¶100

• This single sentence, filed on July 30, 2024, confirms the conduct was ongoing at the time of filing. The complaint was not about a recalled product or a past error. Kimberly-Clark was actively selling lead-containing tampons, unlabeled, as of the complaint date.
• This fact supports the lawsuit’s request for injunctive relief — a court order forcing Kimberly-Clark to stop or disclose — in addition to monetary damages.

Societal Impact Mapping: Who Gets Hurt and How

Public Health

The public health consequences of this conduct extend far beyond one plaintiff in San Diego. Lead’s toxicity is cumulative, systemic, and disproportionately severe for the populations using this product.

• Lead accumulates in bone tissue over time and re-releases into the blood during periods of calcium mobilization, including pregnancy and lactation. A person who used these tampons for years before the lawsuit was filed may carry that body burden forward into a future pregnancy — without ever knowing why.
• The WHO and the complaint both specifically identify women of childbearing age as a high-risk population for lead exposure. Tampons are almost exclusively used by people in exactly that demographic. The overlap is not incidental; it is the core public health crisis embedded in this product.
• Lead inhibits neurological function and is associated with cognitive impairment. There is no threshold below which this effect stops. A person using Super Plus tampons regularly could be absorbing up to 3.358 mcg of lead per day vaginally — directly into circulation — for days every month, for years.
• Because the exposure route bypasses the liver, users have no metabolic defense. Oral lead exposure is already dangerous. Vaginal lead exposure, as the complaint’s cited research confirms, enters systemic circulation without any first-pass filtration. The body cannot partially protect itself the way it can with ingested toxins.
• The complaint cites the toxic shock syndrome outbreak of the 1980s as precedent for the established scientific understanding that toxins can pass through the vaginal epithelium and reach systemic circulation. The mechanism that made TSS deadly is the same mechanism that makes vaginal lead absorption a credible and serious health risk.
• The class is estimated at hundreds of thousands of California purchasers alone. The product is sold nationally. The total number of people exposed cannot yet be calculated from this document, but the class action structure suggests the plaintiff’s attorneys believe it is massive.

Economic Inequality

The economic harm in this case layers on top of pre-existing inequalities in healthcare access and consumer information. It does not land evenly.

• Plaintiff Barton paid between $7.00 and $13.99 per box. For many low-income consumers, that price point represents a considered purchase. The complaint notes that individual class members’ claims are likely too small to justify individual lawsuits — which means the only path to any remedy is collective action. Without this lawsuit, most affected people would have no recourse at all.
• Kimberly-Clark’s motive, per the complaint, was financial: disclosing lead would hurt sales. The company made a business calculation that hiding a health risk was more profitable than disclosing it. That calculation was made at the direct expense of consumers who had no ability to detect the omission.
• The complaint argues that Kimberly-Clark gained an “unfair competitive advantage” by omitting the lead disclosure. Competitors who tested their products and either remediated or disclosed contamination would face lower sales. Kimberly-Clark’s silence was a market strategy that rewarded deception.
• There are other menstrual products on the market. The complaint makes this point explicitly: consumers were deprived of making an informed choice between products because the information was withheld. That deprivation falls hardest on people who do not have the time, resources, or health literacy to independently investigate every product they buy at a drugstore.
• Lead-related health damage — neurological impairment, kidney disease, reproductive harm — generates long-term healthcare costs. For uninsured or underinsured consumers, those costs could be catastrophic. Kimberly-Clark bears none of them under the current regulatory framework unless courts order restitution.

The “Cost of a Life” Metric

What Now: How to Apply Pressure and Protect Yourself

Kimberly-Clark is a Delaware corporation headquartered in Irving, Texas. It manufactures, markets, distributes, labels, and sells U by Kotex Click tampons through retail chains including CVS, Target, and Rite Aid. The lawsuit demands injunctive relief — a court order forcing disclosure or removal — in addition to restitution for all class members.

Leadership Roles Referenced in the Complaint

• The complaint names Kimberly-Clark Corporation as the defendant. Specific executives are not named in this document. [REDACTED – Not in Source]
• The complaint identifies Kimberly-Clark’s agents and employees as parties who prepared, approved, and disseminated the misleading labeling and advertising. No individual names are provided in the source document.

Watchlist: Regulatory Bodies With Jurisdiction

• California OEHHA (Office of Environmental Health Hazard Assessment): The agency that administers Proposition 65, which the complaint cites as a predicate violation. OEHHA can require Prop 65 warnings independently of this lawsuit. File a complaint at oehha.ca.gov.
• Federal Trade Commission (FTC): Has jurisdiction over deceptive advertising practices in consumer products. The label claims — “no harsh ingredients,” “gynecologist tested” — fall squarely within the FTC’s false advertising enforcement authority. File a report at reportfraud.ftc.gov.
• U.S. Food and Drug Administration (FDA): Tampons are regulated as Class II medical devices. The FDA can require safety testing, labeling changes, and recalls. The complaint notes the label claims are not FDA-mandated, but the agency retains device oversight authority. Contact the FDA’s MedWatch program at fda.gov/safety/medwatch.
• Consumer Product Safety Commission (CPSC): Has authority over hazardous consumer products. A tampon delivering lead above a state-established reproductive toxicity threshold is a plausible candidate for CPSC review. File a hazard report at saferproducts.gov.
• California Attorney General’s Office: Can bring enforcement actions under the Unfair Competition Law and Proposition 65 independent of private litigation. Contact the Public Inquiry Unit at oag.ca.gov.

Mutual Aid, Organizing, and Grassroots Resistance

• Stop buying U by Kotex Click compact tampons in all sizes (Regular, Super, Super Plus) until Kimberly-Clark discloses testing results or reformulates the product. The complaint confirms they were still selling the same product as of July 30, 2024.
• Share the original complaint document with every menstruating person in your network. The class is limited to California purchasers in this filing, but lead-contaminated products do not stop at state lines. Awareness is the first line of protection for everyone outside the class.
• Demand ingredient and contaminant transparency from every menstrual product brand you use. Ask manufacturers directly: have your products been independently tested for heavy metals, including lead, arsenic, and mercury? Request published test results before purchasing.
• Support period equity organizations that provide free menstrual products to low-income communities. Those communities are most vulnerable to corporate misconduct and least likely to have access to legal remedies. Donate to local mutual aid networks and period poverty initiatives in your area.
• Contact your state and federal representatives to demand mandatory heavy metal testing and disclosure requirements for menstrual products sold in the United States. No federal law currently requires tampon manufacturers to test for or disclose the presence of heavy metals.
• If you purchased U by Kotex Click tampons in California within the past four years, preserve your receipts and purchase records. Monitor ClassAction.org and the case docket (Case No. 3:24-cv-01337-GPC-KSC, S.D. Cal.) for updates on class certification and any settlement offers.